COMPANY PROFILE

GenomiCare Biotechnology

Explore full profile

GenomiCare Biotechnology is a Chinese precision cancer medicine service company

Huangpu, ChinaFounded 2015Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2018

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About GenomiCare Biotechnology

GenomiCare Biotechnology operates in the biotechnology sector, specializing in the development of next-generation cancer therapeutics. The company leverages multi-dimensional real-world data from Chinese cancer patients, proprietary AI-based data mining algorithms, and self-developed clinical and theoretical knowledge maps to identify novel therapeutic targets. GenomiCare serves pharmaceutical companies, research institutions, and healthcare providers by offering high-quality real-world data, customized computational pipelines, and comprehensive analysis reports. The business model revolves around providing data intelligence services that aid in the discovery of new biomarkers, drug targets, and the design and prediction of clinical trials. Revenue is generated through service contracts, data licensing, and collaborative research agreements. The company operates in a niche market focused on oncology and personalized medicine, aiming to accelerate the development of cancer therapeutics through innovative data solutions.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Huangpu, China
Employees: 18
Open positions: None listed
Dealroom signal: 67.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning GenomiCare Biotechnology.

See all news

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Dec 2018	$30M	$120M	Trustbridge Partners	—
SERIES A✓Equity / VC	Dec 2017	$0	—	Undisclosed	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

GenomiCare Biotechnology website traffic

Latest recorded traffic for GenomiCare Biotechnology is 20 monthly website visits, down 33.3% over the last three months. GenomiCare Biotechnology's team declined 5.3% over the past year.

Latest monthly visits20 3-month web change-33.3% 1-year team growth-5.3%

Monthly website visitsDec 2018–Sep 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GBGeneCast BiotechnologyIt is a Beijing cancer diagnosis company	Haidian, China	Operational	26	$243M	$596M
OOOvaGene OncologyAnd commercializes molecular diagnostics for women	Irvine, United States	Operational
GEGeneAssessNew jersey-based biotechnology company working to validate fry, a cancer molecular signature gene	New Brunswick, United States	Operational
NENeoDiagnostixNeoDiagnostix is committed to pioneering the field of personalized medicine through cancer genomics	Rockville, United States	Operational
ASAlpine Immune SciencesImmunotherapy startup focused on developing recombinant, protein-based therapeutic solutions	Seattle, United States	Acquired
XPXanthus PharmaceuticalsOnline search and redirects	Cambridge, United States	Acquired
ARargenxPlatform for antibody lead choice that supports the discovery of human antibody therapeutics	Ghent, Belgium	Operational
ADAdmeraAdmera Health \| A Molecular Diagnostics Company	South Plainfield, United States	Operational